Eszopiclone is a nonbenzodiazepine hypnotic of the cyclopyrrolone class and the active S-stereoisomer of zopiclone. It belongs to the family of drugs colloquially known as "Z-drugs." First approved by the FDA in 2004 for the treatment of insomnia, it is notable for being one of few hypnotic sedatives approved for long-term use. Eszopiclone enhances GABAergic neurotransmission in a manner similar to yet distinct from benzodiazepines and is considered habit-forming.
Еззопиклон molecular structure diagram from the DrugsPRO substance library.
Also known as: Eszop, Lunesta
Classification
Chemical: Medicine
Chemical: Z-drug
Psychoactive: Depressant
Psychoactive: Psychedelic
Tag: Cyclopyrrolone
Tag: Habit-Forming
Tag: Hallucinogen
Tag: Hypnotic
Effects
Sedation
Muscle Relaxation
Headache
Nausea
Dry Mouth
Anxiolytic
Cognitive Fatigue
Amnesia
Anxiety Suppression
Emotion Suppression
Motor Control Loss
Dizziness
Disinhibition
Internal Hallucination
External Hallucination
Dulled Perception
Taste Distortion
Color Enhancement
Routes of Administration
Oral
Dosage
Heavy: 6 mg
Light: 0.5 – 2 mg
Common: 2 – 3 mg
Strong: 3 – 6 mg
Threshold: 0.5 mg
Duration
Onset: 0.17-0.33 h
Peak: 0.5-1.5 h
Harm Reduction
Check interactions before mixing substances, pay attention to dose spacing and hydration, and treat all dosage guidance as approximate rather than guaranteed safe.
Sources
Substance data is aggregated from the following public harm-reduction and reference sources.
This static page is intended as a readable non-JS and prerender-friendly library export.
Get the full DrugsPRO experience
Open the interactive DrugsPRO app for search, saved items, interactions, and deeper harm reduction tools.
Get the PRO test kit. The simple, quick and reliable drug checking test kit. Visit https://protestkit.eu
Eszopiclone - DrugsPRO ръководство за вещества
Eszopiclone: Eszopiclone is a nonbenzodiazepine hypnotic of the cyclopyrrolone class and the active S-stereoisomer of zopiclone. It belongs to the family of drugs colloquially known as "Z-drugs." First approved by the FDA in 2004 for the treatment of insomnia, it is notable for being one of few hypn